Trevena, Inc. (NASDAQ: TRVN) Starts Presentation at the 2017 Marcum Microcap Conference
Trevena (NASDAQ: TRVN) is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO. Trevena also has discovered TRV250, in early clinical development for the treatment of migraine, and TRV734 for pain. The Company maintains an early stage portfolio of drug discovery programs. For more information, visit the company's website at www.trevenainc.com About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides to users (1) access to our news aggregation and syndication servers, (2) enhanced press release services,…







